Dishman Carbogen Amcis is a contract development and manufacturing organization for pharmaceutical APIs, anchored by its Swiss Carbogen Amcis sites doing drug substance work for big pharma and biotech, plus Indian plants at Bavla and Naroda, a French drug product facility, and a marketable molecules franchise in vitamin D analogs and cholesterol. Roughly 83 percent of FY26 revenue of about INR 2,930 crores came from the CDMO segment, which closed FY26 at a 19.3 percent consolidated EBITDA margin against 17.3 percent in FY25. That margin level sits in the good-but-not-exceptional band for manufacturing, but the mix underneath matters more: late-phase development work runs above 30 percent margins, Swiss commercial around 25 percent, and Indian commercial 35 to 40 percent, while early-phase work drags at 12 to 15 percent. The company works on roughly 700 to 800 programs at any time and holds 13-plus late-phase projects including PPQ campaigns, giving it a funnel that feeds commercial volume over time.
The economics rest on qualification and stickiness rather than price. For the flagship ADC linker-payload program with a Japanese innovator, Dishman is one of only two approved suppliers worldwide and the primary one at roughly 60 percent share, with the linker and payload representing under 1.5 percent of the end product's price, making switching economically irrational for the customer. Twenty-eight commercial-stage molecules have Dishman as sole or primary supplier, customers typically stay through a molecule's life cycle once onboarded, and both Bavla and Naroda hold certifications from all major health authorities, including a US FDA inspection with no observations. The customer-funded co-investments, first CHF 25 million completed and a second CHF 25 million underway with 100 percent partner financing, are direct evidence that customers are willing to capitalise the capacity themselves. This is not a commodity converter; the moat is regulatory qualification plus embedded process knowledge, though customer concentration around one large ADC molecule is real.
The 18-to-24 month picture is a utilisation and refinancing story. In Q1 FY27, revenue fell 4 percent year-on-year to INR 6,776 million because roughly CHF 10 million of shipments were postponed to H2, crushing CDMO EBITDA margin to 6.3 percent; management states that deferred revenue alone translates to close to 70 percent EBITDA addition given a mostly fixed cost base where employee costs are about half the P&L. By mid-FY28, the concrete deltas should be: the US company tech transfer to Bavla completed within FY27 with a second Swiss MNC transfer already initiated and three more in advanced discussion; the second Japanese co-investment operational during calendar 2027 adding roughly CHF 30 million of incremental revenue potential; the newly FDA-approved Phase III molecule generating commercial revenue whose quantum awaits customer forecasts; and the French site still climbing toward breakeven, now expected later than the original FY27 target. Group guidance for FY28-29 is more than 10 percent annual revenue growth with EBITDA margins recovering toward 25 to 26 percent, versus single-digit growth and flat margins in FY27.
The walk-talk record is genuinely mixed. Management delivered FY26 EBITDA margin near its 20 percent guide at 19.3 percent and lifted marketable molecules margin by 940 basis points to 18.8 percent, but missed its own Q3 FY26 revenue phasing by about INR 20 crores on a shipment delay, has pushed the India standalone INR 500 crore milestone from 12-18 months out to FY28 after guiding FY26 India revenue slightly below the FY25 level of INR 400 crores, and has now slipped French breakeven past FY27 despite the February promise of EUR 18 million revenue that year. On capital allocation, the direction is finally right: net debt ex-leases stood at CHF 153.6 million in June 2026, and a promoter-provided ECB of up to CHF 200 million at 4 percent all-in over ten years has RBI approval with conclusion targeted within 60 to 90 days, cutting interest from roughly INR 35-40 crores per quarter toward the INR 30-35 crore level promised since May 2026.
The earnings path quantifies as follows: FY27 closes with single-digit group growth and margins near FY26 levels, then FY28-29 delivers double-digit growth and 25-26 percent EBITDA margins as India grows 30-35 percent in FY27 off a low base, ADC supplies ramp from CHF 22 million in FY25 toward CHF 30-40 million annually, and the effective tax rate falls from about 40 percent toward 30 percent in FY28. What must be true: the ECB actually lands in the next two quarters, the postponed CHF 10 million ships in H2 FY27, tech transfers convert to Indian revenue at the promised pace, and the French RFP pipeline stops slipping. The kill shot is the gap between the 25 percent FY28 margin target and the latest call's softer framing of margins only reaching 25-26 percent by FY28-29; if the ECB slips again or H2 FY27 shipments defer once more, the fixed-cost leverage cuts both ways and FY28 becomes another promise year rather than the inflection.
companyname: Dishman Carbogen Amcis Limited ticker: DCAL sector: Contract Development and Manufacturing Organisation (CDMO) / Pharmaceuticals Dishman Carbogen Amcis Limited is a globally integrated Contract Development and Manufacturing Organisation (CDMO) that serves pharmaceutical and biotech innovators across the drug development lifecycle. The company started in 1983, and over 40 years built a network of 10 manufacturing facilities across India, Switzerland, the UK, France, the Netherlands,...
Read the full report →capex, margin expansion, order book surge, debt reduction
FY27 ADC revenue guided at CHF 30-40 million driven by tech transfer and new contracts; CDMO EBITDA margin target of 25% by FY28
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Dishman Carbogen Amcis Limited and 4,900+ companies.
5-day free pass. No card required.